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Gestational diabetes mellitus (GDM) is a disease commonly occurs during mid to late pregnancy with
pathologies such as hyperglycemia, hyperinsulinemia and mal-development of fetus. We have previously
demonstrated that pancreatic endoderm (PE) derived from human embryonic stem cells (hESCs) effec-
tively alleviated diabetic symptoms in a mouse model of GDM, although the clinical efﬁcacy was limited
due to oxidative stress. In this study, using the anti-oxidant agent naringenin, we aimed to further
enhance the efﬁcacy of hESC-derived PE transplant. Insulin-secreting PE was differentiated from hESCs,
which were then transplanted into GDM mice. Naringenin was administered to mice receiving the PE
transplant, with sham operated mice serving as negative control, to assess its effect on alleviation of
GDM symptoms. We found that naringenin supplement further improved insulin response, glucose
metabolism and reproductive outcome of the PE-transplanted female mice. Our new ﬁndings further
potentiates the feasibility of using differentiated hESCs to treat GDM, in which anti-oxidative agent such
as naringenin could greatly enhance the clinical efﬁcacy of stem cell based therapies.
© 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Gestational diabetes mellitus (GDM) is a condition that affects
pregnant women with pathologies such as hyperglycemia, hyper-
insulinemia, insulin resistance and fetal mal-development (1).
Patients typically exhibit no prior signs of diabetes, and are diag-
nosed with GDM at the second trimester during pregnancy, among
which 3e5% remain diabetic even after pregnancy (2). In addition
to commonmaternal diabetic symptoms, GDM is also accompanied
by mal-development in fetuses (3). The exact molecular mecha-
nisms underlying GDM are yet elusive, although it's thought to be
multifactorial, that involve both genetic predisposition and envi-
ronmental factors (4). For instance, mutations in the pancreatic
b-cell KATP channel subunits Kir6.2 and SUR1 were found to cause
hyperinsulinism and often diabetes mellitus (5). Choice of life style,s; PE, pancreatic endoderm;
tive oxygen species; NGN,
u).
rmacological Society.
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d/4.0/).such as high-saturated-fat diet, was also shown to be able to induce
glucose abnormalities among pregnant women (6).
Several animal models were developed for GDM investigations,
among which the C57BL/KsJ-Lepdb/þ (db/þ) mouse resulted from a
loss-of-function mutation in the leptin receptor gene Lepr (7),
served as a promising model in several GDM studies including our
own (8), by closely mimicking symptoms of human GDM patients.
Prior to pregnancy, the heterozygous mutant mouse exhibits
largely normal glucose tolerance until late gestation (9,10). In
addition, fetal development was also found to be defective, with
5e8% increase in fetal weight at birth (11,12).
Recent developments in stem cell technology provided
exciting advances in the treatment of diabetes. Particularly, hu-
man embryonic stem cells (hESCs) were used to differentiate to
insulin-secreting pancreatic endoderm (PE), which was suc-
cessfully shown to treat diabetic mice (13,14). In addition, large
scale in vitro differentiation of human induced pluripotent stem
cells (hiPSCs) was recently made possible, and glucose-
responsive insulin-producing pancreatic b cells were generated
(15). These cells were capable of secreting human insulin into
the serum and relieving hyperglycemia after being transplanted
in diabetic mice.nese Pharmacological Society. This is an open access article under the CC BY-NC-ND
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followed by transplant into db/þ GDM mice (8). We demonstrated
that the hESC-derived PE transplant could alleviate maternal dia-
betic symptoms and reproductive outcome of the pregnant GDM
mice. However, one limitation of our previous study was that large
quantities of differentiated PE cells were needed for a successful
transplant in order to completely attenuate GDM symptoms. This
was likely due to locally induced oxidative stress at injury sites
resulted from the exogenous PE transplant (16). Increased level of
reactive oxygen species (ROS) like H2O2 and other pro-
inﬂammatory factors poses as a constant challenge for stem cell
transplant based therapies. In this context, agents that antagonize
oxidative stress could contribute to maintenance of the balance by
reducing the ROS levels, and help to ameliorate cellular
dysfunction.
Naringenin (5,7,40-trihydroxyﬂavanone; NGN) is the most
abundant ﬂavanones found in fruits such as grapefruit, lemon,
tangerine and orange (17), and it exhibits many pharmacological
effects including anti-oxidant activities in various animal studies
(18e20). In a rat model of diabetic neuropathy, NGN was found to
ameliorate oxidative stress and nerve growth factor discrepancy
(21). In another rat model of type 2 diabetes, NGN was able to
alleviate cognitive deﬁcits via oxidative stress, pro-inﬂammatory
factors and the PPARg signaling pathway (22). In high-cholesterol
fed rats NGN attenuated renal and platelet purinergic signaling
perturbations by suppressing ROS and NF-kB signaling pathways
(23).
In our current study, we aimed to take advantage of the anti-
oxidant activities of NGN to further enhance the beneﬁcial effect
of hESC-derived insulin-secreting PE transplant, in alleviating GDM
symptoms of pregnant db/þ female mice. Compared with our
previous study, amount of transplanted PE were lowered to half in
order to serve as a sub-optimal baseline treatment. NGN was
administered to mice receiving PE transplant, with sham operated
mice as negative control, to assess its effect on GDM symptoms.2. Materials and methods
2.1. In vitro differentiation of hESCs
H1 hESC lines were cultured using mTeSR1 medium (Stemcell
Technology) on Matrigel (BD Biosciences) coated culture plates and
passaged as previously described (24). The four-stage differentia-
tion protocol was carried out as previously described (13). Key
stages were brieﬂy summarized as follows: 1) H1 hESCs were
transitioned to deﬁnitive endoderm (DE). At 75% conﬂuency, H1
hESCs were washed brieﬂy with 1 phosphate buffered saline
(PBS), then cultured with RPMI medium containing 100 ng/mL
activin supplemented with 0, 0.2% and 0.2% (v/v) FBS (Hyclone) on
days 1e3, respectively. Wnt3a was added to Day 1 medium at ﬁnal
concentration of 25 ng/mL to improve the transition. 2) DE was
further differentiated to endoderm of the primitive gut tube (PG).
DE was cultured for 3 days with RPMI medium containing 2% FBS
and supplemented with 50 ng/mL FGF10 and 20 ng/mL KAAD-
cyclopamine (CYC). 3) PG cells were treated with 0.5 mM retinoic
acid (RA) together with 20 ng/mL CYC and 50 ng/mL FGF10 in
DMEM supplemented with 1% B27 (Invitrogen) for 3 days to
become PDX1-expressing posterior foregut endoderm (PF) cells. 4)
PF cells were further transformed into pancreatic and endocrine
lineages. During 3 days of culture, RA was removed from the me-
dium and 1 mM DAPT and 50 ng/mL exendin-4 (Ex4) were added
into the medium. Cells after stage 4 were characterized by co-
expression of PDX1, FOXA2, and SOX9 and were referred as
pancreatic endoderm (PE).2.2. Cell viability assay
Cells grown in 96-well plates were treated with H2O2 and/or
NGN as indicated. 10 mL of 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT, 5 mg/mL) was added to each
well followed by incubation at 37 C for 4 h in dark. The mediawith
MTT was then removed and the formazan crystals were solubilized
by adding 100 mL of DMSO per well. The reduction of MTT was
quantiﬁed by reading the absorbance at 570 nm by microplate
reader.
2.3. Cellular ROS assay
Cellular ROS level was measured by DCFH-DA (Life Technolo-
gies) following manufacturer's instructions. In brief, cells were
washed twice with pre-warmed serum-free medium, and incu-
bated with 5 mM DCFH-DA in serum-free medium for 30 min, fol-
lowed by washing with PBS. Fluorescent signals were quantiﬁed
from 9 randomly picked regions of interest from three independent
experiments.
2.4. Oxidative stress assays
Oxidative stress was measured by the activity of superoxide
dismutase (SOD), the level of glutathione (GSH) and malondialde-
hyde (MDA). SOD activity was determined by Superoxide Dismut-
ase Assay Kit (Cayman Chemical, UK) following the manufacturer's
instructions, where cell lysate was mixed with the reaction mixture
followed by initiation with NADH and termination with glacial
acetic acid, and absorbance at 560 nm was measured by a micro-
plate reader. GSH levels were measured using the GSH Assay Kit
(Cayman Chemical), where cell lysate was mixed with 5,5-
dithiobes-(2-ni-trobenzoic acid) (DTNB) and phosphate buffer
and absorbance at 412 nm was measured by a microplate reader.
MDA levels were measured using method described earlier (25),
where cell lysate was heated with thiobarbituric acid at 95 C for
40 min, then centrifuged at 3500 rpm for 10 min, then supernatant
was collected and absorbance at 532 nm was measured by a
microplate reader.
2.5. Quantitative RT-PCR
Total RNAwas isolated from cells using the RNeasy MiniPrep Kit
(Qiagen) following manufacturer's instructions. 1 mg of total RNA
was reverse-transcribed with Superscript II First-Strand Synthesis
kit (Life Technologies) as recommended by the manufacturer.
GAPDH mRNA levels were measured for normalization and all data
were presented as relative expression. Primers used in this study
were: OCT4 forward 50-CGT GAA GCT GGA GAA GGA GAA GCT G-30,
reverse 50-AAG GGC CGC AGC TTA CAC ATG TTC-30; PDX1 forward
50-AAG TCTACC AAAGCT CAC GCG-30, reverse 50-GTA GGC GCC GCC
TGC-30; FOXA2 forward 50-GGG AGC GGT GAA GAT GGA-30, reverse
50-TCA TGT TGC TCA CGG AGG AGT A-30; SOX9 forward 50-AGT ACC
CGC ACT TGC ACA AC-30, reverse 50-ACT TGT AAT CCG GGT GGT CCT
T-30; GAPDH forward 50-GTG GAC CTG ACC TGC CGT CT-30, reverse
50-GGA GGA GTG GGT GTC GCT GT-30.
2.6. Glucose-stimulated insulin secretion assay
Glucose-stimulated insulin secretion assay was performed ac-
cording to previously established methods (15). Brieﬂy, PE clusters
were washed with Krebs buffer and were then pre-incubated in
2 mM glucose for 2 h to remove residual insulin. Clusters were then
washed twice, incubated in 2 mM glucose for 30 min, and super-
natant collected. Then clusters were washed again, incubated in
B.-h. Xing et al. / Journal of Pharmacological Sciences 131 (2016) 93e100 9520 mM glucose for another 30 min, and supernatant collected.
Clusters were then dispersed into single cells and cell number was
counted. Concentration of secreted insulin in the supernatant
samples was measured using the 1-2-3 UltraSensitive Mouse In-
sulin ELISA kit (ALPCO Diagnostics) following the manufacturer's
instructions.
2.7. Animals and transplant of hESC-derived cells
The care and use of animals in this study followed the guidelines
and protocol approved by the Institutional Animal Care and Use
Committee (IACUC) of Hebei Medical University. The IACUC com-
mittee members at Hebei Medical University approved this study.
All efforts were made to minimize the number of animals used and
their suffering. Six-week-old micewere housed with fresh food and
water, temperature (22 C ± 2 C), humidity (40%e60%), and light
(12-hour/12-hour light/dark) for two weeks. The rodent diet with
18% protein, 5% fat was provided (Harlan Teklad, Madison, WI). The
PE were transplanted into db/þ female mice (db/þ PE). Four weeks
after transplant, breeding was conducted overnight in a 1:2 ratio,
and mating was conﬁrmed by presence of a vaginal mucous plug
the following morning, which represented gestation day 0 (GD 0).
Pregnant mice were arbitrarily assigned to 1 of 4 groups in a
generalized randomized complete block design, with 12 mice per
group: 1) wild type female mice receiving sham transplant; 2) db/þ
NGN: db/þ female mice receiving sham transplant and adminis-
tered with NGN at 50 mg/kg body weight; 3) db/þ PE: db/þ females
receiving PE transplant untreated with NGN; 4) db/þ PEþNGN: db/
þ females receiving PE transplant pretreated with NGN as well as
administered with NGN at 50 mg/kg body weight. Mice were
anesthetized with inhalable isoﬂurane and received transplants of
3  106 stage 4 hESC-derived pancreatic endoderm cells under the
left kidney capsule. After transplant all mice were treated with oral
enroﬂoxacin (Bayer Animal Health) for 1 week (100 mg/mL in
drinking water).
2.8. Body weight, blood glucose, and plasma insulin
Body weight, blood glucose, and plasma insulin were measured
according to established methods (26). Measurements were per-
formed at gestation day 0 (GD 0), GD 10 and GD 20. Body weight
was measured on a top-loading balance (Accu-622; Fisher Scien-
tiﬁc), and nonfastingmaternal blood samples were obtained via tail
venipuncture to determine insulin and glucose levels. Blood
glucose levels were determined by glucometer (Lifescan Surestep)
and plasma insulin levels were quantiﬁed by ELISA.
2.9. Statistical analysis
All data were presented as mean ± SD. Numbers of independent
experiments or animals were indicated in respective ﬁgure legends.
The data were analyzed by student's t test or a one-way analysis of
variance (ANOVA) followed by pairwise multiple comparisons to
determine any difference between groups (Tukey). Values were
determined to be statistically different when p < 0.05.
3. Results
3.1. NGN improved cell viability of hESCs following H2O2 treatment
First of all, the effect of NGN on cell viability was determined by
treating the hESCs with increasing concentrations of NGN (0, 50,
100 and 200 mg/mL) for 24 h, followed by MTT assay. As shown in
Fig. 1B, hESCs cultured in media supplemented with 100 mg/mL
NGN for 24 h exhibited optimal effect in improving cell viability,showing an average of 40.9 ± 6.1% increase in viability over that of
control. Next in order to induce oxidative stress, we incubated the
hESCs in media containing increasing concentrations of H2O2 (0.25,
0.5 and 1 mM) for 24 h (Fig. 1C), and found that the viability of
hESCs exhibited a dosage-dependent reduction with H2O2 treat-
ment. 0.25 mM H2O2 was chosen as the dose for further analysis
since it exerted mild adverse effect on cell viability with an average
of 81.6 ± 6.0% to the viability of control, whereas higher concen-
trations (0.5 and 1 mM) of H2O2 so severely affected cells that NGN
failed to restore viability (data not shown). In order to assess
whether NGN was able to protect the hESCs from H2O2-induced
reduction of viability, we also treated the cells with medium only
as control, 0.25 mMH2O2, as well as a combination of 0.25 mMH2O2
plus 100 mg/mL NGN, and then measured their viability after in-
cubation in respective media for 0, 12 and 24 h (Fig. 1D). Compared
with the control at 0 h, treatment with H2O2 alone exhibited a
time-dependent inhibition on cell viability, whereas the combi-
nation of H2O2 and NGN was able to improve hESC viability
signiﬁcantly over that of H2O2 treated culture throughout the
experiment. Particularly at 24 h, viability of hESCs in the
H2O2þNGN treatment groupwas even signiﬁcantly higher than the
control group.
3.2. NGN reduced H2O2-induced oxidative stress in hESCs
As exposure to H2O2 waswidely known to cause the production
of cellular ROS, we next investigated whether the observed
beneﬁcial effects of NGN on H2O2-induced reduction of viability
was mediated through reducing oxidative stress. In this context,
hESCs were treated similarly, with medium only as control, 100 mg/
mL NGN, 0.25 mM H2O2 or a combination of 0.25 mM H2O2 plus
100 mg/mL NGN, respectively for 24 h, followed by DCFH-DA
staining to determine cellular ROS production (Fig. 2A). NGN
treatment alone didn't exhibit any signiﬁcant effect on ROS levels,
while as expected, H2O2 treatment alone increased cellular ROS
levels in the culture by an average of 37.9 ± 8.3% over that of
control. Whereas ROS levels in the H2O2þNGN co-treatment group
was signiﬁcantly reduced by an average of 18.8 ± 7.5% to the H2O2
only group, indicating that the addition of NGN in the H2O2-
treated culture was able to reduce cellular ROS production. Besides
ROS, the activity of superoxide dismutase (SOD), levels of gluta-
thione (GSH) and malondialdehyde (MDA) were also measured in
our study as indicators of oxidative stress, to further validate the
anti-oxidative effect of NGN in the hESC culture. As shown in
Fig. 2B and C, SOD activity and GSH level in the H2O2-treated
cultures were signiﬁcantly decreased than their respective con-
trols. Furthermore, the production of MDA in the H2O2-treated
cells was also signiﬁcantly increased compared to control (Fig. 2D).
These results indicated that H2O2 strongly induced oxidative stress
in the in vitro cultured hESCs. Importantly, co-treatment with H2O2
and NGN could restore the SOD activity as well as GSH and MDA
levels to almost the same as their respective controls, suggesting
that NGN indeed could signiﬁcantly attenuate H2O2-induced
oxidative stress.
3.3. Characterization of hESC-derived pancreatic endoderm (PE)
Following previously published four-stage differentiation pro-
cedures (13), we differentiated hESCs to pancreatic endoderm (PE).
Using quantitative RT-PCR, we conﬁrmed the cell lineage by
examining the relative expression levels of the PE speciﬁc marker
genes (Fig. 3). Consistent with our earlier report (8), the differen-
tiated cells indeed had completely shut down OCT4 expression to
less than 3% of that in undifferentiated hESCs (Fig. 3A), and greatly
increased expressions of PDX1, FOXA2 and SOX9 by at least over 40
Fig. 1. Naringenin (NGN) improved cell viability following H2O2 treatment in human embryonic stem cells (hESCs). (A) Chemical structure of naringenin. (B and C) Relative cell
viability of hESCs to the empty vehicle control (DMSO for NGN, and water for H2O2) after treatment with NGN (B) or H2O2 (C), respectively at concentrations indicated, normalized
against completely untreated cells. (D) Relative cell viability of hESCs to the control, after treatments with empty vehicle control, 0.25 mM H2O2 or 0.25 mM H2O2 plus 100 mg/mL
NGN, respectively at indicated times. Values were mean ± SD from four independent experiments. *p < 0.05, **p < 0.01, vs respective control; #p < 0.05, vs H2O2 treatment group.
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hESC-derived cells generated by our four-stage protocol closely
matched committed pancreatic endoderm in the embryo (27).
Next we tested the ability of the hESC-derived PE to secret in-
sulin responding to acute high glucose challenge. The PE clusters
were subjected to glucose-stimulated insulin secretion assay, by
sequential incubation with low (2 mM) and high (20 mM) levels of
glucose (Fig. 3E). Again consistent with our previous report (8),
when challenged with high level glucose, insulin secreted by the PE
was increased signiﬁcantly (0.48 ± 0.16 mIU/103 cells) compared
with low glucose (3.15 ± 0.27 mIU/103 cells), demonstrating the
ability of the hESC-derived PE to produce and secret insulin stim-
ulated by glucose. To our surprise, when the hESC-derived PE
clusters were treated with NGN, their insulin response to 20 mM
glucose challenge (4.52 ± 0.37 mIU/103 cells) was further enhanced
than that in the absence of NGN.
3.4. NGN enhanced the alleviating effect of PE transplant on GDM
symptoms in pregnant db/þ mice
We have previous reported that PE transplant could alleviate
GDM symptoms of pregnant db/þ mice (8), since NGN could in-
crease the insulin secretion ability of PE clusters, we speculate NGN
might potentially further enhance the beneﬁcial effects of the PE
clusters. In this context, femalemicewere divided to four treatment
groups: 1) wild type female mice receiving sham transplant; 2) db/
þ female mice receiving sham transplant and administered with
NGN at 50 mg/kg body weight (db/þ NGN); 3) db/þ females
receiving PE transplant (db/þ PE); 4) db/þ females receiving PE
transplant as well as administered with NGN at 50 mg/kg body
weight (db/þ PEþNGN). Four weeks after transplant, breeding was
conducted andmating was conﬁrmed, which represented gestationday 0 (GD 0). Of note, 3  106 stage 4 hESC-derived PE cells were
transplanted into each mice, half of the amount as previously
transplanted (8). We thenmeasured the steady state levels of blood
glucose and insulin levels throughout the pregnancy. As illustrated
in Fig. 4A, blood glucose levels of wild type females remained stable
from GD 0 to 20 (143.5 ± 9.6 mg/dL on GD20), whereas db/þ NGN
mice showed signiﬁcantly elevated blood glucose levels
(207.6 ± 7.9 mg/dL on GD20), which is the characteristic hyper-
glycemia symptom of GDM. On the other hand, blood glucose levels
of db/þ PE females were signiﬁcantly reduced by the PE transplant
(182.4 ± 7.6 mg/dL on GD20), although not completely reduced to
normal levels as the wild type control. NGN administration was
able to further reduce the steady state glucose levels to
151.2 ± 8.0 mg/dL on GD20, which was statistically the same as the
wild type control on GD20. In a similar manner, steady state insulin
levels in db/þNGNmice (0.604 ± 0.037 mg/L) were also signiﬁcantly
lower than the wild type (0.793 ± 0.036 mg/L), suggesting impaired
insulin production. However insulin levels in the GDM mice could
be markedly increased by PE transplant (db/þ PE: 0.697 ± 0.040 mg/
L), and fully restored back to normal with co-treatment of PE
transplant and NGN administration (db/þ PEþNGN:
0.803 ± 0.041 mg/L) on GD20 (Fig. 4B). In addition, maternal body
weight gains in db/þ NGN mice (32.1 ± 0.9 g) were signiﬁcantly
higher than the wild type (25.9 ± 0.9 g) (Fig. 4C), and the PE
transplant was able to bring the excess weight gain back to
28.9 ± 0.8 g on GD20. As expected, administration of NGN in PE-
transplanted db/þ PEþNGN mice exhibited the same trend of
maternal body weight gain as the wild type control throughout the
pregnancy, with average body weight on GD20 at 26.1 ± 0.8 g.
Taken together, the above results clearly demonstrated that NGN
could enhance the beneﬁcial effects of PE transplant on GDM
symptoms in pregnant db/þ mice.
Fig. 2. NGN H2O2-induced oxidative stress in hESCs. hESCs were treated with empty vehicle control, 0.25 mM H2O2 only, 100 mg/mL NGN only or a combination of 0.25 mM H2O2 and
100 mg/mL NGN for 24 h, followed by measurement of cellular ROS level (A), SOD activity (B), GSH (C) and MDA levels (D), normalized against completely untreated cells. Values
were mean ± SD from four independent experiments. **p < 0.01, vs respective control; #p < 0.05, vs H2O2 only treatment; is insigniﬁcant, vs respective control.
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reproductive outcome of GDM female mice
Another adverse consequence of GDM is fetal mal-development,
with less number of offspring as well as abnormally increased fetus
weight at term (11,12,28,29), and our hESC-derived PE transplant
was able to improve fetal development of GDM female mice (8). We
were curious if NGN could enhance the beneﬁcial effect of PE
transplant on reproductive outcome of GDM female mice as well.
Total litter number at birth was counted from the four treatment
groups of female mice (n ¼ 12 each), and their mean litter size was
illustrated in Fig. 5A. The db/þ NGN female mice gave birth to
signiﬁcantly lower number of litters than the wild type dam,
whereas number of litters of the females from the db/þ PE group
were obviously higher. In contrast, litters size of db/þ PEþNGN dam
were almost the same as that of wild type. In addition, the mean
body weight of litters at birth was also analyzed (Fig. 5B). Consis-
tent with previous report, body weight at birth of litters from the
db/þNGN females (1.43 ± 0.05 g) was signiﬁcantly heavier than the
wild type group (1.17 ± 0.07 g), and PE transplant could signiﬁcant
reduce the abnormally increased birth weight to 1.32 ± 0.05 g.
Importantly, administration of NGN to the PE-transplanted dam
was able to reduce the litter weight at birth (1.20 ± 0.05 g)
completely to statistically the same level of wild type control group.
These results clearly indicated NGN enhanced beneﬁcial effects of
PE transplant on reproductive outcome of GDM female mice.
4. Discussion
GDM patients account for almost 10% of all pregnant women
worldwide, and patients affected by GDM have higher long-termrisk of type 2 diabetes (1). As a new therapy to diabetes mellitus,
stem cell based approaches utilizing hESCs and hiPSCs have been
recent performed employing animal models, showing effective and
promising results (13,15), which led to several clinical trials with
positive results in treating diabetes (30). However, treatment for
GDM in particular has not yet been that successful, with by far only
one clinical trial focused on conventional dietary intervention
instead of stem cell therapy (31). Our previous study has provided
the ﬁrst successful report of treating GDM with stem cell therapy
using the db/þmouse GDMmodel (8). We have employed the four
stage differentiation procedures (13), and managed to produce
insulin-secreting PE from hESCs. These hESC-derived PE were then
transplanted into pregnant female GDM mice, where they signiﬁ-
cantly alleviated GDM symptoms including hyperglycemia, hyper-
insulinemia and their reproductive outcome, as well as early
offspring development.
One limitation during our previous investigation was that, a
large quantity of PE was needed for transplants to exhibit signiﬁ-
cantly observable improvement (6  106 stage 4 hESC-derived PE
cells), whereas lowering the amount of PE cells for transplant also
lowered its beneﬁcial alleviating effects on symptoms of GDMmice
(Figs. 4 and 5). It can be deduced that even larger quantity would be
required for prospective human patient transplant to achieve ideal
clinical efﬁcacy. We speculate that the exogenous PE transplant
induced locally induced oxidative stress, which commonly poses as
an adverse challenge for stem cell transplant based therapies (16).
Therefore anti-oxidants might be needed to antagonize this
oxidative stress and help to improve efﬁcacy of stem cell
transplants.
In this current study, we employed the ﬂavanone NGN, whose
anti-oxidative effects were widely reported (18e20). We
Fig. 3. NGN enhanced glucose response of hESC-derived pancreatic endoderm (PE). (A to D) Relative gene expressions of OCT4 (A), PDX1 (B), FOXA2 (C) and SOX9 (D) from hESCs
and hESC-derived PE (see Materials and Methods), in the absence and presence of NGN, respectively. (E) ELISA of secreted insulin from PE clusters, sequentially incubated with
glucose at low (2 mM) and high (20 mM) concentrations for 30 min, in the absence (control) and presence of 100 mg/mL NGN respectively. Values were mean ± SD from three
independent experiments. **p < 0.01, is insigniﬁcant, vs respective hESC control; $p < 0.01, vs respective low glucose treatment; #p < 0.05, vs high glucose control.
Fig. 4. NGN enhanced the alleviating effect of PE transplant on GDM symptoms in pregnant db/þ mice. Serum glucose concentration (A), serum insulin concentration (B) and
maternal body weight (C) were examined on gestation day (GD) 0, 10 and 20 in wild type, db/þ NGN, db/þ PE and db/þ PEþNGN treatment groups of pregnant mice (n ¼ 12 each).
Values were mean ± SD. *p < 0.05, #p < 0.05, is insigniﬁcant, vs wild type mice.
B.-h. Xing et al. / Journal of Pharmacological Sciences 131 (2016) 93e10098hypothesized that anti-oxidant activities of NGN could reduce the
threshold quantity of PE transplant, by reducing cellular oxidative
stress and enhancing its beneﬁcial effects in alleviating GDM
symptoms of pregnant db/þ female mice. First of all by simulating
oxidative stress with H2O2 in in vitro cultured cells, we found that
NGN treatment was able tomarkedly reduced the adverse effects of
H2O2, evidenced by improved cell viability and reduced cellularoxidative stress parameters compared to cells untreated with NGN.
Of note, NGN treatment didn't affect the ability of hESCs to differ-
entiate into insulin-secreting PE cells, using the same four-stage
protocol.
Moreover, NGN appeared to even enhance insulin secretion
responding to glucose challenge in the differentiated PE cells,
which might also contribute to its beneﬁcial effects in vivo. Indeed,
Fig. 5. NGN enhanced effect of PE transplant on reproductive outcome of GDM female
mice. (A) Litter size at birth was counted for each mouse fromwild type, db/þ NGN, db/
þ PE and db/þ PEþNGN dam groups (n ¼ 12 each). (B) Body weight of litters fromwild
type, db/þ NGN, db/þ PE and db/þ PEþNGN dam groups (n ¼ 12 each) were measured
at birth. Values were mean ± SD. *p < 0.05, #p < 0.05, is insigniﬁcant, vs wild type
dams.
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cells, NGN synergized with the transplant and exhibited much
enhanced treatment effects on their diabetic symptoms. The
transplant together with NGN was able to completely attenuate
hyperglycemia and restore impaired insulin production in pregnant
db/þ GDM mice, and reduce their body weight throughout the
pregnancy to the same level as healthy wild type mice. One inter-
esting observation worth pointing out was that plasma insulin
levels of PE-transplanted mice were signiﬁcantly higher upon NGN
administration, which was likely due to the earlier observed
enhancing effect of NGN on insulin secretion in vitro. Indeed, NGN
was found to enhance the glucose-stimulated insulin secretion and
glucose sensitivity in INS-1E cells (32), which suggested that
mechanisms other than anti-oxidative stressmight also be involved
in its enhancing effect on transplanted PE to alleviate GDM symp-
toms. Furthermore NGN also exerted synergistic effect with the PE
transplant in improving reproductive outcome of pregnant GDM
female mice, where both size and weight at birth were restored to
the same level of wild type mice. Taken together, results from our
current study clearly demonstrated that NGN enhanced the efﬁcacy
of hESC-derived PE in treating GDM mice, by greatly reduce the
requirement of PE cell quantity needed for effective transplants.
To summarize the current study, we have applied the anti-
oxidant activities of NGN to enhance the beneﬁcial effect of hESC-
derived insulin-secreting PE transplant, in alleviating GDM symp-
toms of pregnant db/þ female mice. Our results demonstrated that
NGN improved insulin response, glucose metabolism andreproductive outcome of the PE-transplanted female mice, which
supported potential clinical efﬁcacy of combining stem cell trans-
plant based therapy with anti-oxidants in treating GDM.
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